Page 77 - e-book CPG - Bipolar Disorder

CLINICAL PRACTICE GUIDELINES MANAGEMENT OF BIPOLAR DISORDER (2ND ED.)

therapeutic the below younger, in not is levels affect adversely to

POSSIBLE AND COMPATIBLE TO USE IN LACTATION. to adversely affect infant growth or development. but measurable, developmental anticonvulsant or psychotropic drugs. serum infant POSSIBLE TO USE IN LACTATION. does monotherapy growth or development in most infants. the cause can be established.

LACTATION Breastfeeding during carbamazepine monotherapy does not appear Carbamazepine and its active metabolite have relatively high levels in breastmilk and breastfed infants have serum levels that are well usually Most infants have no adverse reactions, but sedation, poor sucking, withdrawal rea

   sometimes range.  reported. Monitoring:  o and Measuring o AEs are observed.  Lamotrigine   dosage.   toxicity. Monitoring:  o concern.
BIPOLAR and malformations and pregnancy. during 63

OF malformations hypoplasia to prior monthly to
TREATMENT congenital fingernail twice up

PREGNANCY FOR Carbamazepine and its active metabolite cross the placenta; May be associated with teratogenic effects, including spina bifida, cardiovascular of Risk Foetal carbamazepine syndrome has been proposed consisting defects, COMPATIBLE - MATERNAL BENEFIT >> EMBRYO-FOETAL Crosses the hu

RECOMMENDED concentrations are variable. defects, delays. increases with higher doses. craniofacial developmental delay. of exposed newborns. to maintain clinical response. measured be then can

NOT DISORDER. craniofacial developmental minor of RISK doses. Monitoring: o should Monitoring partum.
         

MEDICATION Carbamazepine Lamotrigine

MOOD STABILISERS

63